RV521

DRUG4 trials

Sponsors

Pfizer

Conditions

Lower Resp Tract InfectionRespiratory Syncytial Virus (RSV)Respiratory Syncytial Virus Infections

Phase 1

A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants

CompletedNCT03782662

PfizerRespiratory Syncytial Virus Infections

Start: 2018-11-07End: 2019-03-17Updated: 2024-04-22

Pharmacokinetics and Safety of RV521 Formulations

CompletedNCT04065698

PfizerRespiratory Syncytial Virus Infections

Start: 2019-08-13End: 2019-09-09Updated: 2024-06-07

Phase 2

A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection

CompletedNCT03258502

PfizerRespiratory Syncytial Virus Infections

Start: 2017-07-19End: 2017-10-31Updated: 2025-07-31

A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.

TerminatedNCT04225897

PfizerLower Resp Tract Infection, Respiratory Syncytial Virus (RSV)

Start: 2019-11-13End: 2022-12-05Updated: 2024-10-23

Related Papers

Safety and Pharmacokinetics of the RSV Fusion Inhibitor Sisunatovir Across Two Early-phase Studies in Infants and Children With RSV Lower Respiratory Tract Infection.

2026-02-12

A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.

2020-01-2765 citations